Home・Lista de Ações・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Abrir

SetorSaúde

19.03 -2.11

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

18.58

Máximo

19.64

Indicadores-chave
By Trading Economics
Rendimento	25M -43M
Vendas	-3.6M 65M
EPS	-0.48
Margem de lucro	-65.788
Funcionários	298
EBITDA	-16M -31M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+98.51% upside

Dividendos
By Acuity
Próximos Ganhos	4 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-34M 1.8B
Abertura anterior	21.14
Fecho anterior	19.03

Sentimento de Notícias

By Acuity

43%

57%

148 / 340 Ranking em Healthcare

Syndax Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

30 de jul. de 2026, 17:06 UTC

Syndax Pharmaceuticals shares are higher as the broader market recovers, with the S&P 500 advancing following recent volatility in U.S. Treasury yields.

29 de jul. de 2026, 19:56 UTC

Macro Event

Syndax Pharmaceuticals Inc shares are lower, continuing a trend with six consecutive daily declines amid broader market concerns over rising crude oil prices.

28 de jul. de 2026, 20:51 UTC

Syndax Pharmaceuticals Inc is trading lower in after-market hours, continuing a six-session decline amid market focus on the Federal Reserve's interest rate decision.

27 de jul. de 2026, 20:06 UTC

Syndax Pharmaceuticals shares are lower as the broader market declines amid falling oil prices, impacting Treasury yields and investor sentiment.

24 de jul. de 2026, 19:52 UTC

Syndax Pharmaceuticals Inc shares are lower today, continuing a downward trend over the past few days amid broader market pressures.

22 de jul. de 2026, 19:06 UTC

Syndax Pharmaceuticals Inc shares are lower today with no specific news identified. Broader market sentiment is impacted by rising crude oil prices and geopolitical tensions.

Comparação entre Pares

Variação de preço

Syndax Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

98.51% parte superior

Previsão para 12 meses

Média 38.67 USD 98.51%

Máximo 57 USD

Mínimo 29 USD

Com base em 10 analistas de Wall Street que oferecem metas de preço de 12 meses para Syndax Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

10 ratings

Comprar

Manter

Vender

Com base em 10 analistas que deram avaliações de ações para Syndax Pharmaceuticals Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

148 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.